New hope for elderly lymphoma patients: drug combo targets tough cancer

NCT ID NCT06594939

Not yet recruiting Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 21 times

Summary

This study tests whether adding two targeted drugs (mosunetuzumab and polatuzumab vedotin) to standard chemotherapy can help older adults (70+) with a newly diagnosed, aggressive type of lymphoma called diffuse large B-cell lymphoma. About 31 participants will receive this combination to see if it improves complete remission rates. The goal is to find a more effective and tolerable treatment for elderly patients who may not tolerate standard therapy well.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)